Discovery, Synthesis, and in Vivo Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase
Top Cited Papers
- 21 March 2007
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 50 (9), 2213-2224
- https://doi.org/10.1021/jm061335f
Abstract
The Aurora kinases have been the subject of considerable interest as targets for the development of new anticancer agents. While evidence suggests inhibition of Aurora B kinase gives rise to the more pronounced antiproliferative phenotype, the most clinically advanced agents reported to date typically inhibit both Aurora A and B. We have discovered a series of pyrazoloquinazolines, some of which show greater than 1000-fold selectivity for Aurora B over Aurora A kinase activity, in recombinant enzyme assays. These compounds have been designed for parenteral administration and achieve high levels of solubility by virtue of their ability to be delivered as readily activated phosphate derivatives. The prodrugs are comprehensively converted to the des-phosphate form in vivo, and the active species have advantageous pharmacokinetic properties and safety pharmacology profiles. The compounds display striking in vivo activity, and compound 5 (AZD1152) has been selected for clinical evaluation and is currently in phase 1 clinical trials.Keywords
This publication has 16 references indexed in Scilit:
- The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: A new class of Aurora-A kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2006
- Validating Aurora B as an anti-cancer drug targetJournal of Cell Science, 2006
- PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral ActivityClinical Cancer Research, 2006
- SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2006
- Inhibitors of Aurora kinases for the treatment of cancerExpert Opinion on Therapeutic Patents, 2005
- Aurora kinases: shining lights on the therapeutic horizon?Oncogene, 2005
- Potent and Selective Aurora Inhibitors Identified by the Expansion of a Novel Scaffold for Protein Kinase InhibitionJournal of Medicinal Chemistry, 2005
- Aurora-kinase inhibitors as anticancer agentsNature Reviews Cancer, 2004
- Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochoresThe Journal of cell biology, 2003
- The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore–microtubule attachment and in maintaining the spindle assembly checkpointThe Journal of cell biology, 2003